Navigation Links
The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer
Date:5/9/2011

BUFFALO, N.Y., May 9, 2011 /PRNewswire/ -- Kinex Pharmaceuticals, LLC announced today that Dr. Allen Barnett, who served as the Founding Chief Executive Officer, has decided to step aside as CEO.

Dr. Barnett stated "I am delighted to see Kinex Pharmaceuticals evolve from a start-up biotechnology company with only a technology platform to a company with a pipeline of two compounds in pre-IND to phase 2 developments. The recent collaboration established with Hanmi Pharmaceuticals is also an important milestone for Kinex. As the company grows, the need for both scientific and business efforts has increased tremendously. I believe that this is the right time to pass the torch to my successor who will help the company grow. I am delighted to say that I have been able to convince our Executive Chairman, Dr. Johnson Lau to step in to take the lead. I have worked with him for more than a decade in different settings and I am very happy to be able to have somebody with his experience and involvement with Kinex to lead the Company. I remain committed to assist with the growth of Kinex Pharmaceuticals in the many years to come."

Dr. Johnson Lau is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management.  As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals.  Dr. Lau has served as the Senior Director of Antiviral Therapy at Schering-Plough where he played a significant role in the FDA approval of Ribavirin/Interferon and Pegylated interferon alpha-2b. He has more than 250 scientific publications in peer reviewed scientific journals, more than 50 editorials/reviews/chapters and has edited three books. He was a Managing Director at Roth Capital Partners at its headquarters in Newport Beach, California and is also a Director of the Board of Chelsea Therapeutics (NASDAQ: CHTP) and other privately held companies. Dr. Lau has served as the Executive Chairman of Kinex Pharmaceuticals since its inception.

Dr. Lau stated, "Dr. Allen Barnett is a legend in the pharmaceutical industry. Kinex has advanced under his leadership to an early stage pipeline company. He is the grandfather of Kinex Pharmaceuticals. I am delighted that the Board and I have convinced Dr. Barnett to stay on as President Emeritus and allow us to tap into his vast experience in the pharmaceutical industry to support the future growth of Kinex Pharmaceuticals."

Mr. Chuck Lannon, Vice-Chairman of Kinex Pharmaceuticals, stated, "Allen has contributed tremendously to the establishment of Kinex Pharmaceuticals. We thank him for his excellent service and we are delighted to retain him as President Emeritus so that he can continue to support the growth of Kinex Pharmaceuticals with his scientific experience in the many years to come". Mr. Lannon also stated, "I have worked with Johnson for many years. The Board and the management team are extremely supportive of Dr. Lau and are delighted that he is willing to lead Kinex".

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica™ and Opal™ to discover and develop novel drugs for oncology and immune-modulatory diseases.    More information of Kinex Pharmaceuticals can be found at  www.kinexpharma.com

Kinex Pharmaceuticals, LLC – Caution Regarding Forward-looking Information

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Kinex Pharmaceuticals cautions investors that any forward-looking statements or projections made by Kinex Pharmaceuticals, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected..

Kinex Inquiries:

Lyn M. Dyster, Ph.D.
VP, Operations
Kinex Pharmaceuticals
New York Center of Excellence
701 Ellicott Street
Buffalo, NY 14203
USA
Tel: 716.898.8626
E-mail: Ldyster@kinexpharma.com


'/>"/>
SOURCE Kinex Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
2. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
3. American Board of Internal Medicine President Named to Alzheimers Study Group
4. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
5. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
6. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Silence Therapeutics Announces Board Changes
11. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD announces that AB Laboratories ... in its licensed production facility under the Access to ... Hamilton, Ontario . The ... in October 2016, is currently operating at half capacity, ...
(Date:3/23/2017)... 23, 2017 Piramal Pharma ... anuncia el nombramiento de Stuart E. Needleman ... de servicios integrados completa para su base de ... clave en el crecimiento y ejecución de las ... de impulsar todas las actividades de desarrollo empresarial ...
(Date:3/23/2017)... TEL AVIV, Israel, March 23, 2017  Galmed ... or the "Company"), a clinical-stage biopharmaceutical company focused ... for the treatment of nonalcoholic steatohepatitis, or NASH, ... for the three and twelve months ended December 31, ... recently completed pre-clinical studies demonstrating Aramchol™,s potential direct ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... today announced rapid completion of the strategic executive team expansion needed to further ... to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access network. ... experts in dangerous situations the Inflow IQ team can help people. Get ready ... & refreshing knowledge systems that enhance life. , Authentically enjoy 500 ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March ... the US Special Operations Command’s Patriot Award. The award was presented by the ... Force Dagger Foundation for its significant and enduring support to the command. ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony ... the creation of published author Bonetta Rose, a wife, mother and grandmother committed to ... by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in the life ...
(Date:3/23/2017)... ... ... Trainer”: an electrifying and suspenseful gunslinger novel with a twist. “The Trainer” is ... an enthusiasm for action and adventure stories. , Published by Christian Faith ... at the thirty-three notches that lined the edges of the wooden grip plates of ...
Breaking Medicine News(10 mins):